Literature DB >> 28584138

Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?

Audrey Le1, Dimitrios Farmakiotis2, Jeffrey J Tarrand3, Dimitrios P Kontoyiannis4.   

Abstract

The 28-day crude mortality rate in 68 cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia started on treatment (within 48 h after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%) than those treated with azole monotherapy (52%) (P = 0.07). After adjusting for confounders, azole monotherapy also was associated with worse 28-day survival (hazard ratio, 3.8; P = 0.003).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Candida glabrata; azole monotherapy; candidemia; echinocandin; polyenes

Mesh：

Substances：

Year:  2017        PMID： 28584138      PMCID： PMC5527607          DOI： 10.1128/AAC.00631-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation.

Authors:  Dimitrios Farmakiotis; A Kyvernitakis; J J Tarrand; D P Kontoyiannis
Journal:  Clin Microbiol Infect       Date:  2014-10-12       Impact factor: 8.067

2.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

3.  Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

Authors:  David R Andes; Nasia Safdar; John W Baddley; Geoffrey Playford; Annette C Reboli; John H Rex; Jack D Sobel; Peter G Pappas; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

4.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

5.  Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.

Authors:  M Puig-Asensio; M Fernández-Ruiz; J M Aguado; P Merino; D Lora-Pablos; J Guinea; P Martín-Dávila; M Cuenca-Estrella; B Almirante
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.

Authors:  Gregory A Eschenauer; Peggy L Carver; Shu-Wen Lin; Kenneth P Klinker; Yee-Chun Chen; Brian A Potoski; Ryan K Shields; Cornelius J Clancy; Minh-Hong Nguyen; Simon W Lam
Journal:  J Antimicrob Chemother       Date:  2012-12-04       Impact factor: 5.790

7.  The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.

Authors:  Ray Hachem; Hend Hanna; Dimitrios Kontoyiannis; Ying Jiang; Issam Raad
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

Review 8.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2016-02-15       Impact factor: 9.079

Review 9.  Candida glabrata: a review of its features and resistance.

Authors:  C F Rodrigues; S Silva; M Henriques
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-11-19       Impact factor: 3.267

10.  Drug-resistant Candida glabrata infection in cancer patients.

Authors:  Dimitrios Farmakiotis; Jeffrey J Tarrand; Dimitrios P Kontoyiannis
Journal:  Emerg Infect Dis       Date:  2014-11       Impact factor: 6.883
View more
  3 in total

1.  Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.

Authors:  Shaoming Lin; Ruilan Chen; Song Zhu; Huijun Wang; Lianfang Wang; Jian Zou; Jingdong Yan; Xiangdong Zhang; Dimitrios Farmakiotis; Xiaojiang Tan; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2018-03-23       Impact factor: 2.574

2.  Synthesis and Evaluation of New 1,3,4-Thiadiazole Derivatives as Potent Antifungal Agents.

Authors:  Ahmet Çağrı Karaburun; Ulviye Acar Çevik; Derya Osmaniye; Begüm Nurpelin Sağlık; Betül Kaya Çavuşoğlu; Serkan Levent; Yusuf Özkay; Ali Savaş Koparal; Mustafa Behçet; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2018-11-29       Impact factor: 4.411

3.  A predictive nomogram for mortality of cancer patients with invasive candidiasis: a 10-year study in a cancer center of North China.

Authors:  Ding Li; Tianjiao Li; Changsen Bai; Qing Zhang; Zheng Li; Xichuan Li
Journal:  BMC Infect Dis       Date:  2021-01-15       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.